NASDAQ:HALO - Halozyme Therapeutics Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $15.97 -0.39 (-2.38 %) (As of 04/21/2019 10:20 AM ET)Previous Close$15.97Today's Range$15.84 - $16.4852-Week Range$13.24 - $20.54Volume1.06 million shsAverage Volume816,237 shsMarket Capitalization$2.32 billionP/E RatioN/ADividend YieldN/ABeta1.85 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Halozyme Therapeutics (NASDAQ:HALO) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.5 Wall Street analysts have issued ratings and price targets for Halozyme Therapeutics in the last 12 months. Their average twelve-month price target is $20.40, suggesting that the stock has a possible upside of 27.74%. The high price target for HALO is $24.00 and the low price target for HALO is $17.00. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: HoldHoldHoldHoldConsensus Rating Score: 22.214.171.1242.38Ratings Breakdown: 1 Sell Rating(s)2 Hold Rating(s)2 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)2 Hold Rating(s)2 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)3 Hold Rating(s)4 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)3 Hold Rating(s)4 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $20.40$20.40$21.00$21.00Price Target Upside: 27.74% upside18.26% upside36.36% upside28.36% upsideHalozyme Therapeutics (NASDAQ:HALO) Consensus Price Target History Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails2/28/2019Cantor FitzgeraldSet Price TargetBuy$24.00Medium2/27/2019JMP SecuritiesReiterated RatingBuy$21.00Medium10/19/2018Piper Jaffray CompaniesReiterated RatingNeutral ➝ NeutralLow8/8/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$19.00 ➝ $21.00Medium5/11/2018BarclaysDowngradeEqual Weight ➝ Underweight$19.00High2/21/2018Canaccord GenuityBoost Price TargetBuy$19.00 ➝ $21.00High2/21/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$19.00 ➝ $22.00Low1/24/2018Deutsche BankSet Price TargetBuy$21.00Low1/24/2018Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$20.00High8/10/2017Jefferies Financial GroupReiterated RatingUnderperform$6.75 ➝ $7.00High(Data available from 4/21/2017 forward) This page was last updated on 4/21/2019 by MarketBeat.com StaffFeatured Article: How is diluted EPS different from basic EPS?